On Monday September 11, it was announced that Teva Pharmaceutical Industries, the largest maker of generic drugs in the world, had a new President and CEO – 30-year pharmaceutical and health care veteran, Kare Schultz, previously COO at Novo Nordisk and currently CEO and President at H. Lundbeck A/S in Denmark. In February, Teva CEO, Erez Vigodman, left his position …
Pharma Coding – Novartis’ Kymriah Approved By FDA
On August 30th, Novartis’ Kymriah was approved by the U.S. Food & Drug Administration for treating a form of ALL (acute lymphoblastic leukemia) in individuals age 25 and younger. Kymriah, or tisagenlecleucel is a CAR-T (Chimeric Antigen Receptor T-Cell) therapy that, according to reports, is a one-time treatment. The treatment is customized to each patient, as his or her T-cells …
Pharma Marking – Treatment Of Ovarian Cancer Looks Promising
Recently it was announced that CA4P, an ovarian cancer treatment investigation drug of Mateon Therapeutics, was showing favorable results when combined with Roche’s Avastin, (bevacizumab) in a focus study assessing the effectiveness of the combination drugs along with chosen chemotherapy treatment in treating patients with prOC or platinum resistant ovarian cancer. According to reports, CA4P (combretastatin A-4 phosphate) targets the …
Pharma Marking – FDA Approves Vosevi For Hepatitis C
The FDA has recently given approval to Gilead Sciences for the use of the company’s Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets to re-treat adults who suffer from chronic hepatitis C virus infection, or HCV. According to reports, the single-tablet regimen is effective in most patients; two studies supported the claim that about 96% of patients involved in …
Pharma Coding – Opana ER Pulled From Market Following FDA Request
Everyone knows opioid painkillers have been in the news for quite some time, as these drugs have been found to be highly addictive and abused. Recently it was announced that Endo would pull Opana ER from the market after the FDA asked the pharmaceutical manufacturer to pull the drug about 30 days ago. Opana ER, or oxymorphone hydrochloride, is reported …